Results 11 to 20 of about 4,690 (200)

Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.

Journal of Cystic Fibrosis, 2022
BACKGROUND Many individuals with cystic fibrosis (CF) have chronic rhinosinusitis resulting in nasal obstruction, sinus infections, and repeated surgeries.
Amanda L. Stapleton, A. Kimple, J. Goralski, S. Nouraie, B. Branstetter, Amber D. Shaffer, J. Pilewski, B. Senior, Stella E Lee, A. Zemke   +9 more
semanticscholar   +3 more sources

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

Frontiers in Pharmacology, 2023
Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ) and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF).
Burkhard Tümmler, Burkhard Tümmler
doaj   +3 more sources

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine, 2021
Rationale: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic fibrosis transmembrane conductance regulator) allele, but it has not ...
Edith T. Zemanick, J. Taylor-Cousar, J. Davies, R. Gibson, M. Mall, E. McKone, P. McNally, B. Ramsey, J. Rayment, S. Rowe, E. Tullis, N. Ahluwalia, C. Chu, Thang V. Ho, S. Moskowitz, S. Noel, S. Tian, D. Waltz, Tanya G Weinstock, F. Xuan, C. Wainwright, S. McColley   +21 more
semanticscholar   +1 more source

Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis

Hepatology Communications, 2023
The cystic fibrosis (CF) transmembrane conductance regulator corrector/potentiator combinations lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor improve sweat chloride, pulmonary function, and nutrition.
Steven Levitte, Yonathan Fuchs, Russell Wise, Zachary M. Sellers   +3 more
doaj   +1 more source

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine, 2023
Rationale Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to be safe and effective in people with cystic fibrosis (CF) aged ⩾6 years with at least one F508del-CFTR allele but has not been studied in younger children.
J. Goralski, J. Hoppe, M. Mall, S. McColley, E. McKone, B. Ramsey, J. Rayment, P. Robinson, F. Stehling, J. Taylor-Cousar, E. Tullis, N. Ahluwalia, A. Chin, C. Chu, Mengdi Lu, Tao Niu, Tanya G Weinstock, F. Ratjen, M. Rosenfeld   +18 more
semanticscholar   +1 more source

Personalized Selection of a CFTR Modulator for a Patient with a Complex Allele [L467F;F508del]

Current Issues in Molecular Biology, 2022
The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators.
Elena Kondratyeva, Nataliya Bulatenko, Yuliya Melyanovskaya, Anna Efremova, Elena Zhekaite, Viktoriya Sherman, Anna Voronkova, Irina Asherova, Alexander Polyakov, Tagui Adyan, Valeriia Kovalskaia, Tatiana Bukharova, Dmitry Goldshtein, Sergey Kutsev   +13 more
doaj   +1 more source

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.

Journal of Cystic Fibrosis, 2021
BACKGROUND Though weight gain has been reported in some clinical trials of CFTR modulators, the effect of elexacaftor-tezacaftor-ivacaftor on body weight, body mass index (BMI), blood pressure, lipids and glycemic control in the real-world setting ...
Max C. Petersen, Lauren Begnel, M. Wallendorf, M. Litvin   +3 more
semanticscholar   +1 more source

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes

Journal of Clinical & Translational Endocrinology, 2023
Aims: Combined CFTR modulator therapies have dramatically altered pulmonary outcomes in patients with cystic fibrosis (CF). Their impact on glucose metabolism requires further investigations.
Fabian Lurquin, Sophie Gohy, Michel P. Hermans, Vanessa Preumont   +3 more
doaj   +1 more source

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.

Journal of Cystic Fibrosis, 2023
BACKGROUND Phase 3 clinical trials showed elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was safe and efficacious in people with cystic fibrosis (CF) with ≥1 F508del-CFTR allele.
J. Bower, N. Volkova, N. Ahluwalia, G. Sahota, F. Xuan, A. Chin, Tanya G Weinstock, Josh Ostrenga, A. Elbert   +8 more
semanticscholar   +1 more source

Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis

Thorax, 2023
Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) has been shown to improve lung function in people with cystic fibrosis (PWCF). However, its biological effects remain incompletely understood.
M. Casey, C. Gabillard-Lefort, O. Mcelvaney, O. McElvaney, T. Carroll, R. Heeney, C. Gunaratnam, E. Reeves, M. Murphy, N. G. Mcelvaney   +9 more
semanticscholar   +1 more source